209968-94-5

Upstream product

• 209968-91-2 Toluene-4-sulfonic acid (2R,3R,3aS,9aS)-2-(6-benzoylamino-purin-9-yl)-3-hydroxy-5,5,7,7-tetraisopropyl-dihydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-9a-ylmethyl ester 
• 209968-90-1 Toluene-4-sulfonic acid (2S,3S,4R,5R)-5-(6-benzoylamino-purin-9-yl)-3,4-dihydroxy-2-hydroxymethyl-tetrahydro-furan-2-ylmethyl ester 
• 63592-90-5 N⁶-benzoyl-5'-hydroxymethyl-O^2'_,O3'-isopropylidene-adenosine 
• 206055-56-3 [(2S,3S,4R,5R)-4-acetoxy-5-(6-benzamidopurin-9-yl)-3-benzyloxy-2-(benzyloxymethyl)tetrahydrofuran-2-yl]methyl acetate 
• 206055-61-0 N-[9-[(2R,3R,4S,5R)-4-benzyloxy-5-(benzyloxymethyl)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]purin-6-yl]benzamide 
• 206055-66-5 N-[9-((1S,3R,4R,7S)-7-Benzyloxy-1-benzyloxymethyl-2,5-dioxa-bicyclo[2.2.1]hept-3-yl)-9H-purin-6-yl]-benzamide 
• 206055-48-3 4-C-acetoxymethyl-1,2-di-O-acetyl-3,5-di-O-benzyl-D-ribofuranose 
• 153186-10-8 ((3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 293751-18-5 1-(2-O-acetyl-3-O-benzyl-4-C-methanesulfonoxymethyl-5-O-methanesulfonyl-β-D-erythro-pentofuranosyl)-6-N-benzoyladenine 
• 293751-33-4 ((1R,3R,4R,7S)-3-(6-benzamido-9H-purin-9-yl)-7-(benzyloxy)-2,5-dioxabicyclo[2.2.1]heptan-1-yl)methylbenzoate 
• 293751-32-3 ((1R,3R,4R,7S)-3-(6-benzamido-9H-purin-9-yl)-7-(benzyloxy)-2,5-dioxabicyclo[2.2.1]heptan-1-yl)methyl methanesulfonate 
• 293751-13-0 (1R,3R,4R,7S)-3-(adenine-9-yl)-7-benzyloxy-1-benzoyloxymethyl-2,5-dioxabicyclo[2.2.1]heptane 
• 293751-12-9 (1R,3R,4R,7S)-3-(adenine-9-yl)-7-benzyloxy-1-methanesulfonoxymethyl-2,5-dioxabicyclo[2.2.1]heptane 
• 293751-34-5 ((1S,3R,4R,7R)-3-(6-amino-9H-purin-9-yl)-7-(benzyloxy)-2,5-dioxa-bicyclo-[2.2.1]heptan-1-yl)methanol 

Downstream Products

• 206055-74-5 N-(9-((1R,3R,4R,7S)-1-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl)-9H-purin-6-yl)benzamide 

Relevant academic research and scientific papers

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1', X1, B1

IMPROVED SYNTHESIS OF ?2.2.1|BICYCLO NUCLEOSIDES

A synthesis of [2.2.1]bicyclo nucleosides which is shorter and provides higher overall yields proceeds via the key intermediate of the general formula III, wherein R4 and R5 are, for instance, sulfonates and R7 is, for instance, a halogen or an acetate. F

A simplified and efficient route to 2′-O, 4′-C-methylene-linked bicyclic ribonucleosides (locked nucleic acid)

A novel efficient method for the synthesis of locked nucleic acid (LNA) monomers is described. The LNA 5′,3′-diols containing thymine, 4-N-acetyl- and 4-N-benzoylcytosine, 6-N-benzoyladenine, and 2-N-isobutyrylguanine as nucleobases were prepared via convergent syntheses. The method is based on the use of the common sugar intermediate 1,2-di-O-acetyl-3-O-benzyl-4-C-methanesulfonoxymethyl- 5-O-methanesulfonyl-D-erythro-pentofuranose (8) that easily can be prepared from D-glucose in multigram scale. Four different nucleobases were stereoselectively coupled to 8 using a modified Vorbrueggen procedure to give the corresponding 4′-C-branched nucleoside derivatives. Subsequent ring closing furnished the protected LNA nucleosides. The 5′-O-mesyl groups were efficiently displaced by nucleophilic substitution using sodium benzoate. Saponification of the 5′-benzoates followed by catalytic removal of the 3′-O-benzyl groups afforded the free LNA diols. The exocyclic amino groups of adenosine and cytidine were selectively acylated to give 4-N-acetyl- or 4-N-benzoyl-LNA-C and 6-N-benzoyl-LNA-A. The isobutyryl group of guanine was retained during the preparation of 2-N-isobutyryl-LNA-G. The LNA-T diol and base-protected LNA diols can be directly converted into LNA-phosphoramidites for automated chemical synthesis of LNA containing oligonucleotides.

Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides

LNA (Locked Nucleic Acids) is a novel oligonucleotide analogue containing [2.2.1]bicycle nucleoside monomers. A novel and significantly improved method for convergent synthesis of LNA [2.2.1]bicycle nucleosides using a 4-C-tosyloxymethyl-1,2-di-O-acetyl furanose as a key synthon is described. In addition, an alternative, robust linear approach allowing selective formation of the desired [2.2.1]bicyclo LNA nucleosides via a tricyclic nucleoside intermediate is introduced.

LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition

LNA (Locked Nucleic Acids), consisting of 2'-O,4'-C-methylene bicyclonucleoside monomers, is efficiently synthesized and its nucleic acid recognition potential evaluated for six different nucleobases, namely adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil. Unprecedented increases (+3 to +8°C per modification) in the thermal stability of duplexes towards both DNA and RNA were obtained when evaluating mixed sequences of partly or fully modified LNA. Studies of mis-matched sequences show that LNA obey the Watson-Crick base pairing rules with generally improved selectivities compared to the corresponding unmodified reference strands.